AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03950401 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nylon
Description: wound closure using nylon suture on the skin
Study NCT04171804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Participants will receive a total of 10 stimulation sessions on 5 consecutive days (twice a day with 3-4 hours interval). During each session, 2 milliAmpers (mA) of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
Study NCT04171804 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Participants will receive a total of 10 stimulation sessions on 5 consecutive days (twice a day with 3-4 hours interval). During each session, 2 milliAmpers (mA) of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
Study NCT01853163 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gadolinium analysis in bone and tissue samples
Description: Gadolinium analysis in bone and tissue samples from patients undergoing an orthopaedic surgical procedure who had received GBCAs in the past.
Study NCT02848053 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT06570876 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: The decision between RS and CS depended on the patient's performance status; on the cyst's main characteristics and contact with liver structures; and on intraoperative findings.
Study NCT02223689 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin Affix
Study NCT01222403 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluad_MF59-adjuvanted trivalent influenza subunit vaccine
Study NCT02578420 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: open-label placebo
Description: Placebo Cream, openly described as Placebo
Study NCT02578420 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: deceptive placebo
Description: Placebo Cream, described as Voltaren, containing Diclofenac
Study NCT01222403 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine
Study NCT00381953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Study NCT00735800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Intervention:Telephone Tracking Support- Caregiver
Description: Family-based problem solving treatment
Study NCT00735800 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Support
Description: Supportive telephone counseling about caregiving
Study NCT00861978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: St. John's Wort extract
Description: Coated tablets (batch no. 02080277) containing 300 mg of St. John's Wort extract LI 160 (drug-extract ratio 3-6:1; extraction solvent: 80% Methanol in water; batch no. 02019073) administered orally twice daily (morning and evening) with some liquid for 8 weeks
Study NCT00861978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Coated placebo tablets (batch no. 01010177) that were identical in shape, size, taste and color were administered orally twice daily (morning and evening) with some liquid for 8 weeks.
Study NCT03997942 — intervention group
Intervention type: OTHER
Intervention: Effect of exercise
Description: Once the data are available, we hope to have information about which of the exercise practices included in the rehabilitation program of acute upper extremity burn patients is more effective.
Study NCT03250780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: indigo-carmine 0.2% using a spray catheter
Study NCT03250780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.03% using a foot pump
Study NCT04105985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kovanaze Nasal Spray
Description: Intra-nasal local anesthetic
Study NCT04105985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine Injection
Description: Local anesthetic
Study NCT04237454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Imaging Camera
Description: To develop a non-ionising radiation-based method of excluding fractures in children with suspected physical abuse
Study NCT02059915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation X, single dose, under fed conditions
Study NCT02059915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
Study NCT02059915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
Study NCT02059915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
Study NCT01684488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YRI
Description: The YRI brings together six empirically-supported practice elements shown to be efficacious across different mental health interventions, as well as methods intended to socialize youth and improve self-efficacy. Practice elements address the broad scope of problems evidenced in Sierra Leonean war-affected youth and enhance the YRI's pacing, which progresses through three phases traditionally used in trauma treatments (stabilization, integration, connection). The weekly intervention takes place over 10 sessions lasting approximately one hour and a half. Groups are divided by gender and age. Each group is paired with two interventionists of the same gender.
Study NCT01684488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EducAid educational programming
Description: EducAid is a charitable trust that provides free year-round education to over 1,500 youth, along with food, medicine, and shelter when needed. EducAid's education model aims to improve academic knowledge, self-efficacy, and attitudes toward school. Additionally, it aims to nurture hope for the future and a sense of normalcy through interactions with teachers, mentors, and peers.
Study NCT01684488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EducAid educational programming
Description: EducAid is a charitable trust that provides free year-round education to over 1,500 youth, along with food, medicine, and shelter when needed. EducAid's education model aims to improve academic knowledge, self-efficacy, and attitudes toward school. Additionally, it aims to nurture hope for the future and a sense of normalcy through interactions with teachers, mentors, and peers.
Study NCT00381953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon alfa-2a
Study NCT00381953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study NCT00406640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desvenlafaxine succinate sustained-release (DVS SR)
Description: flexible dose of DVS 50-100 or 200 mg every day during 56 days. Extension until 6 months.
Study NCT00406640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Flexible dose of Escitalopram 10 or 20 mg every day during 56 days. Extension until 6 months.
Study NCT01755273 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Pancreaticoduodenectomy with more distal enteral bypass
Description: Patients undergoing pancreaticoduodenectomy, the enteral bypass (gastrojejunostomy/duodenojejunostomy is extra 100 cm away from standard bypass )
Study NCT03953183 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: P3P-1mg
Description: P3P-1mg (P3P product containing 1mg of nicotine.)
Study NCT03953183 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: P3P-2mg
Description: P3P-2mg (P3P product containing 2mg of nicotine.)
Study NCT03709641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Defyne
Description: Restylane is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL
Study NCT02658058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Landmark technique
Description: The site of needle insertion will be determined via manual palpation. A line joining the superior aspect of the iliac crests posteriorly (Tuffier's line') will be used as a surface landmark for the L4 vertebral body. The midline will be established by palpation of the tips of the spinous processes, and the site of needle insertion will be marked on the patient's skin. The interspace that appears widest, based on manual palpation, will be chosen for the first attempt. If the first attempt is unsuccessful, further attempts can be made at the same interspace or another interspace.
Study NCT02658058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided paramedian technique
Description: The transducer will be applied in the parasagittal plane and the intervertebral levels will be identified by counting upwards from the sacrum (continuous hyperechoic line). The probe will then be angled obliquely to obtain a PSO view. The locations of the interlaminar spaces will be identified by visualizing the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body. The angulation at which the ligamentum flavum-dura mater complex and posterior vertebral body are best visualized will be considered the optimal angle for needle insertion and clearly communicated to the operator. The interlaminar space will be centered on the ultrasound screen and a skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe.
Study NCT02658058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided midline technique
Description: The transducer will be applied in the parasagittal plane, and after identification of the intervertebral levels, the probe will be rotated 90 degree to obtain the TM view. The transducer is moved in a cephalad-caudad direction between the spinous processes of L2 and L5 vertebra. The probe will be tilted slightly up and down to ensure a sufficient echogenic window at the selected intervertebral space. A skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe. The angle at which the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body are best visualized will be noted
Study NCT02896374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Theory of mind without visual cues
Description: Theory of mind stimulation without visual reinforcement while performing EEG recordings
Study NCT02965534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacle/Glasses
Study NCT03284385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO
Study NCT02965534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacle/Glasses
Study NCT04061798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT guided heparinization
Description: If the ACT is \<180 sec., an additional dose of heparin of 60 IU/kg is administered. If the ACT is 180-200 sec., 30 IU/kg.~If the ACT is >200 sec., no extra heparin is given. 5 min. after every administration of heparin the ACT is measured. If the ACT is >200 sec, the next ACT measurement is performed every 30 min., until the end of the procedure or until new heparin administration is required. After each new dose of heparin, an ACT measurement is performed after 5 min. and the above- described protocol of ACT measurements will be repeated. After re-establishing blood flow and removing all clamps, the ACT is measured.~If the ACT at closure is 200-250 sec., 2500 IU of protamine should be administered. If >250 sec., 5000 IU protamine. If 180-200 sec., 1000 IU protamine. 5 min. after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 sec. If the ACT is still more than 200 sec., protamine should be administered again.
Study NCT04061798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 000 IU of heparin
Description: A single dose of 5 000 IU of heparin is given 3-5 min before clamping of the aorta. No ACT measurements are performed, except for one ACT measurement after re-establishing blood flow and removing all clamps. Only on clarified indications extra doses of heparin or protamine are permitted, at the discretion of the attending vascular surgeon. Indications could be clot formation intravascular or in a prosthesis, excessive bleeding or prolonged operation duration. Deviations from protocol should be clearly stated with reasoning in the operative report.~If the ACT at closure is between 200 and 250 s, 2500 IU protamine should be administered. If the ACT is higher than 250 s, 5000 IU protamine should be administered. If the ACT is between 180 and 200 s, 1000 IU protamine should be administered. Five minutes after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 s. If the ACT is still more than 200 s, protamine should be administered again.
Study NCT03978494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf®
Description: Advagraf®1 mg and 5 mg prolonged-release hard capsules once daily (reference medicinal product).
Study NCT02896374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Theory of mind without visual cues
Description: Theory of mind stimulation with visual reinforcement while performing EEG recordings
Study NCT01727908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopy with staining of the mucosa
Description: Staining of the gastric mucosa with acetic acid and Indigocarmine
Study NCT03964766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotary instrumentation
Description: using pedo rotary files in cleaning and shaping the root canals of infected primary molars
Study NCT03978494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic tacrolimus
Description: Tacrolimus 1 mg and 5 mg prolonged release hard capsules (Sandoz) once daily (test medicinal product)
Study NCT04318743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glepaglutide
Description: GLP-2
Study NCT01797198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: Oral
Study NCT01797198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: Oral
Study NCT01797198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Oral
Study NCT03964766 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand instrumentation
Description: using conventional hand files in cleaning and shaping the root canals of infected primary molars
Study NCT04926454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients will be monitored using standard monitoring (heart rate, non-invasive blood pressure, ECG and pulse oximetery) After the child is adequately anesthetized, intra-venous access with appropriate size cannula will be obtained Appropriate size LMA (2 and 2.5) will be inserted and patients will be allowed to breathe spontaneously.~patients will receive 0.25% Bupivacaine (0.3ml/Kg) with 1 μg/kg dexmedetomidine After general anaesthesia
Study NCT02241512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Study NCT02241512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00521339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: 20 mg PO (by mouth) twice per day (BID) for 84 days and then an additional 84 days during the optional treatment extension period. For subjects meeting the dose escalation criteria, dosage during the optional treatment extension period can be increased to 30 mg BID.
Study NCT02851511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Cognitive Training employs an eight component, PositScience BrainHQ suite via its researcher portal.
Study NCT04477304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opioid Naive, OR
Description: Visits where the order is for an included opioid and there is no prior opioid prescription with a start date of greater than 1 day and less than 91 days and clinician is on the clinic list as a treating member of the clinic
Study NCT04477304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: At-risk for long-term use, OR
Description: Visit where the order is for an included opioid, there is a prior opioid prescription with a start date greater than 1 day and less than 91 days, and there is no prior opioid prescription with a start date greater than 90 days and clinician is on the clinic list as a treating member of the clinic
Study NCT04477304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long-term opioid recipient
Description: Total opioid doses are at least 50 MME per day, there are two or more prior opioid prescriptions with two different start dates both greater than 1 day and less than 91 days, and there is a prior opioid prescription with a start date greater than 90 days and less than 181 days and clinician is on the clinic list as a treating member of the clinic
Study NCT02375698 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H56:IC31
Description: H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c).
Study NCT02375698 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of 10mM Tris and 169 mM NaCl pH 7.4.
Study NCT00496873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: 600 mg/m\^2 on Day 1 of 21-day cycle.
Study NCT00496873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipent
Description: 4 mg/m\^2 on Day 1 of 21 Day Cycle.
Study NCT06449287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: The diet intervention will start after all baseline testing is complete
Study NCT00496873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: 375 mg/m\^2 on Day 1 of 21 Day Cycle.
Study NCT06449287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: The diet intervention will start after all baseline testing is complete
Study NCT04793672 — intervention group
Intervention type: OTHER
Intervention: Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.
Description: Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.
Study NCT06449287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Blood samples will be collected biweekly.
Study NCT00536731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbuhaler
Description: Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
Study NCT00536731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort pMDI
Description: Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
Study NCT06449287 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood Draw
Description: Blood samples will be collected biweekly.
Study NCT00536731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pulmicort Turbuhaler
Description: Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
Study NCT02402907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate (CHG) cloth
Description: administration of a 2% CHG cloth at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
Study NCT02402907 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cloth
Description: administration of a cloth with the placebo (commercial cleansing cloth) at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
Study NCT06449287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ketone/Glucose Monitoring
Description: Hand-held glucometer will be used daily to monitor dietary intervention adherence.
Study NCT06449287 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ketone/Glucose Monitoring
Description: Hand-held glucometer will be used daily to monitor dietary intervention adherence.
Study NCT06449287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Composition
Description: DEXA Scanning will be done pre-, mid-, and post- intervention.
Study NCT06449287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body Composition
Description: DEXA Scanning will be done pre-, mid-, and post- intervention.
Study NCT06449287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urine Analysis
Description: 24 hour urine collection will be done biweekly.
Study NCT06449287 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Urine Analysis
Description: 24 hour urine collection will be done biweekly.
Study NCT01096771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ClinOleic 20%
Description: 96 hour continuous infusion.
Study NCT01096771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%
Description: 96 hour continuous infusion.